AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 131 min read

HC Wainwright & Co. reiterates Buy rating on Incyte, $152 price target

HC Wainwright & Co. reiterated a Buy rating on Incyte (INCY) with a $152 price target, suggesting a 36.5% upside from the Oct 12 close. The firm cited strong pipeline potential, particularly for drug INCB161734, with a 69% response rate in untreated patients and projected annual sales of $700 million in the U.S. G12D pancreatic cancer market.

Original reporting
tradingview.com
Published Oct 13, 2026, 10:36 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. reiterates Buy rating on Incyte, $152 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Med
01

Why it matters

The reiterated Buy and higher target could attract new buying interest, supporting short‑term price gains.

02

Market read

Analyst upgrade with a specific price target provides a fresh catalyst for Incyte's stock.

03

What to watch

Potential regulatory hurdles and competition in the G12D pancreatic market could temper upside.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

Analyst note from HC Wainwright highlighting Incyte's pipeline and market potential.

Market effects

Sector

Biotech sector may see modest uplift from positive trial data and analyst optimism.

Regional

U.S. biotech investors could increase exposure to Incyte and similar pipeline companies.

Global

Limited to investors tracking US‑listed biotech stocks.

Counterpoint

What could challenge this read

The price target may be overly optimistic if trial results do not translate to commercial sales.

Key entities

  • Company
    Incyte Corporation

    Biopharmaceutical company developing oncology drugs.

  • Research Firm
    HC Wainwright & Co.

    Equity research boutique issuing the rating.

Read at source← All news

Related articles

OCT 13
$SNDXHighAI 8/10

Syndax shares fall as lung fibrosis drug fails trial

Syndax Pharma's shares fell 17% pre-market after abandoning its IPF drug axatilimab, which failed a phase 2 trial. The drug, partnered with Incyte, is approved for cGVHD as Niktimvo. Incyte's shares also dipped slightly. Syndax reported $152M in 2025 revenue, with $115M in the first half of 2026.

pharmaphorum.com2 min
OCT 7
$INCYMed

Incyte (INCY) Won New Approvals, Is The Pullback A Cheap Entry?

Incyte (INCY) received U.S. approval for Atebrioz and Brazil's expedited approval for NIKTIMVO. Shares are down 6.52% in 7 days and 10.50% in 30 days, but up 11.85% year-to-date and 32.86% in 1 year. The stock trades 14% below the average analyst price target. Incyte's 2026 guidance projects total net sales of $5.13B-$5.26B and Opzelura net sales of $1.05B-$1.10B. Analysts value the stock at $128.48, while a DCF model values it at $93.58.

simplywall.st2 min
OCT 5
$INCYMed

Stifel raises Incyte stock price target on pipeline potential

Stifel raised its price target on Incyte Corp. (NASDAQ:INCY) to $157 from $145, citing its undervaluation and pipeline potential. The firm expects $3.7B revenue by 2029 and $10B peak sales from late-stage pipeline. Other analysts also adjusted targets, noting FDA approvals and strategic agreements. Incyte trades at a P/E of 14.6 and PEG of 0.18.

investing.com2 min
OCT 4
$INCYHighAI 9/10

Incyte Wins FDA Approval for Rare Bone Disease Drug

Incyte (INCY) received FDA approval for Atebrioz, a treatment for fibrodysplasia ossificans progressiva. The drug, licensed to Mirum Pharmaceuticals (MIRM), showed a 3.2 cm³ reduction in lesion volume in trials. Incyte also received a Rare Pediatric Disease Priority Review Voucher. Mirum plans U.S. launch in October.

mychesco.com2 min
OCT 3
$MRKHigh

Big Pharma Bets $2.2 Billion on Previously 'Undruggable' KRAS G12D; Race for Pancreatic Cancer Targeted Therapies Heats Up

Merck and Bayer have invested billions in KRAS G12D inhibitors for pancreatic cancer, with Merck paying $2.13B for a preclinical candidate. Johnson & Johnson and Eli Lilly are also developing therapies, while Revolution Medicines' RMC-6236 received FDA approval. Competition is intense, with first-to-market advantages and high commercial potential.

finance.biggo.com3 min